Diagnosis: Recurrent Hepatocellular Carcinoma
The immunohistochemical profile of CK7-negative, CK20-negative, and glypican-3-positive strongly indicates recurrent hepatocellular carcinoma (HCC) in your patient with prior hepatectomy for HCC. 1
Immunohistochemical Interpretation
The staining pattern is highly characteristic of HCC:
Glypican-3 positivity is a specific marker for hepatocellular malignancy, with 100% specificity when combined with other markers in the diagnostic panel for HCC 1
CK7-negative and CK20-negative pattern is the classic immunoprofile of HCC, distinguishing it from cholangiocarcinoma (which would be CK7-positive/CK19-positive) and metastatic colorectal carcinoma (which would typically be CK20-positive) 2, 1
While CK7 can be positive in 44% of HCC cases in non-cirrhotic livers 3, and rare HCC variants may show atypical cytokeratin patterns 4, 5, the combination of negative CK7/CK20 with positive glypican-3 makes HCC the definitive diagnosis 1
Recommended Additional Immunohistochemical Confirmation
To solidify the diagnosis, complete the hepatocellular marker panel:
Arginase-1, CD10, pCEA, and BSEP should be ordered, as these have superior specificity and sensitivity compared to HepPar-1 and glypican-3 alone 1
Hepatocyte Paraffin-1 (HepPar-1) can provide additional confirmation of hepatocellular differentiation 1, 6
Consider CK19 staining to assess prognosis, as CK19-positive HCC predicts early postoperative recurrence (within 2 years), increased invasiveness, and higher rates of extrahepatic metastasis including lymph node involvement 7
Critical Management Steps
Immediate Staging Workup
Multiphase CT of chest, abdomen, and pelvis is mandatory to assess extent of recurrence and identify extrahepatic disease 8, 9
Liver MRI with hepatobiliary contrast should be performed to characterize all hepatic lesions and assess vascular involvement 1
Alpha-fetoprotein (AFP) level should be measured, as elevated AFP correlates with immunohistochemical AFP positivity and helps monitor disease 10, 3
Multidisciplinary Tumor Board Review
Urgent referral to hepatobiliary specialist and multidisciplinary team (hepatology, surgical oncology, interventional radiology, transplant surgery) is required for treatment planning 4, 10
Assessment must include liver function status, presence of cirrhosis, portal hypertension, and performance status to determine treatment eligibility 1
Treatment Considerations Based on Recurrence Pattern
Surgical resection or ablation if solitary recurrence with adequate liver reserve 1
Liver transplantation evaluation if within Milan criteria and appropriate candidate 1
Systemic therapy (atezolizumab-bevacizumab, lenvatinib, or sorafenib) for multifocal or unresectable disease 1
Locoregional therapy (TACE, radioembolization) for intermediate-stage disease 1
Important Prognostic Caveat
If CK19 staining is positive, this indicates aggressive biology with high risk of early recurrence and extrahepatic spread, which should influence treatment intensity and surveillance frequency 7. This subset represents a progenitor cell phenotype with significantly worse outcomes 4, 7.